

Stockholm, 2018-10-12

## **PRESS RELEASE**

### **Additional warrants in incentive programs assigned to senior executives and key employees**

The Extraordinary General Meeting of QuiaPEG Pharmaceuticals Holding AB (publ) ("the Company") decided on 29<sup>th</sup> June 2018 to establish a warrant-based incentive program for senior executives within the QuiaPEG Group through the issue of up to 1,000,000 warrants with the right to subscribe for new shares in the Company, and approval of the transfer of such options. The warrants could only be subscribed to by the company's wholly owned subsidiary, QuiaPEG Pharmaceuticals AB ("Subsidiary"), that has the entitlement and obligation to transfer the warrants to senior executives within the QuiaPEG Group on one or more occasions in accordance with the allocation decided by the Board.

All warrants have been subscribed to by the Subsidiary and the warrants have been registered with the Swedish Companies Registration Office. With full exercise of the warrants, the number of shares in the company will increase by 1,000,000 shares. The purpose of the inclusion of the incentive program P01 2018/2022 is the Board's desire to promote the Company's long-term interests by offering senior executives and other key employees the opportunity to take part in an incentive program that enables them to participate in the Company's value development and contributes to the Company's ability to retain senior executives and key employees. This is expected to increase involvement in operations among senior executives and key employees. The Board is of the opinion that it is important to confer increased ownership commitment on senior executives and key employees which is expected to have a positive impact on the Company's continued development and thus benefit the Company and its shareholders.

The Subsidiary has previously transferred 600,000 warrants to the CEO and key persons.

On October 11<sup>th</sup>, 2018, the subsidiary transferred the remaining 400,000 warrants to senior executives and key employees involved in the subsidiary's operations. This means that the entire incentive program is now implemented. The warrants are distributed as follows.

Steen Krøyer (Chairman of the Board) - 210,000 warrants

Lars Linzander (Board member) - 60,000 warrants

Jonas Jarvius (Board member) - 20,000 warrants

Christian Krog-Jensen (Board member) - 20,000 warrants

Jim Van Alstine (Consultant in the role of Scientific Advisor, mainly patents) - 30,000 warrants

Vidar Wendel Hansen (Consultant in the role of Chief Medical Officer) - 30,000 warrants

Mats Reslow (Consultant in the role of Project Manager) - 30,000 warrants

The transfer price has been fixed at 48 öre per warrant calculated according to the "Black & Scholes" formula. The subscription price for the exercise of warrants for subscription of new shares has been fixed at SEK 3.94 per share, which corresponds to the Company's volume-weighted average price in the period between 18<sup>th</sup> June 2018 and 29<sup>th</sup> June 2018 multiplied by 2.0.

For further information contact: Marcus Bosson

CEO

Tel: +46 (0) 70 693 12 53

E-mail: [marcus.bosson@quiapeg.com](mailto:marcus.bosson@quiapeg.com)

[www.quiapeg.com](http://www.quiapeg.com)

*This information is such that QuiaPEG Pharmaceuticals Holding AB (publ.) is obliged to disclose under the EU Market Abuse Regulation and the Securities Market Act. The information was provided, through the above contact person, for publication on October 12<sup>th</sup>, 2018.*